Pieter Cullis


Contact via University of British Columbia


Key Research Areas
Associated Researchers
Associated Organizations

Recent Research Projects

NanoMat: NSERC CREATE Training Program in Nanomaterials Science & Technology

2014/15-2019/20 • $1,650,000 • PI,CO
Substances with dimensions that are less than 100 nm ("nanomaterials") often have new and surprising properties, including magnetic, optical, mechanical and electronic effects. Integrating nanomaterials into devices and applications (e.g., solar cells, sensors, drug delivery) can give companies...

Commercialization Advisory Board

2015/16 • $5,000 • PI
No summary

Life Sciences Institute (LSI) Startup Competition

2015/16 • $5,000 • PI
No summary

A scale-up microfluidic-based manufacturing process for the production of therapeutic lipid nanoparticles: a I2I phase 2b project

2012/13-2013/14 • $350,000 • PI,CO
"A scale-up microfluidic-based manufacturing process for the production of therapeutic lipid nanoparticles" is a collaborative project between investigators at the University of British Columbia (UBC) and a Vancouver-based start-up company, Precision NanoSystems (PNI).Nanoparticles are small,...

CSI @ LSI Science Education Outreach Program

2011/12-2013/14 • $30,000 • PI
No summary

Patents

CATIONIC PEG-LIPIDS AND METHODS OF USE

The present invention provides cationic-polymer-lipid conjugates (CPLs) such as distal cationic-poly(ethylene glycol)-lipid conjugates which can be incorporated into conventional and stealth liposomes or other lipid-based formulation for enhancing cellular uptake. The CPLs of the present invention comprise a lipid moiety; a hydrophilic polymer; and a polycationic moiety. Method of increasing intracellular delivery of nucleic acids are also provid ed.
Related applications: EP20000920309, WO2000CA00451, CA20002370690

IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and...
Related applications: CA20083044134, EP20080866209, EP20160163003, CA20082709875, WO2008US88676

MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES

Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the...
Related applications: EP20090750195, CA20092725535, EP20090750195, ES20090750195T, WO2009IB06532, CA20092910133, CA20092989616

Improved amino lipids and methods for the delivery of nucleic acids

The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipid having the structure below and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses....
Related applications: WO2009US60251, CA20092984026, EP20160206100, ES20090819991T, EP20140156047, EP20140156047, CA20092740000, EP20090819991

REVERSE HEAD GROUP LIPIDS, LIPID PARTICLE COMPOSITIONS COMPRISING REVERSE HEADGROUP LIPIDS, AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS

The present invention related to a novel class of zwitterionic lipids that are useful in the preparation of lipid particles suitable for the delivery of encapsulated nucleic acids to cells.
Related applications: WO2010US54351

COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES

Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that binds a Na+/K+ ATPase to enhance uptake of the lipid particle b\ the cell Related compositions useful in practicing methods include lipid particles comprising a conjugated compound that enhances uptake of the lipid particles b\ the cell The methods and...
Related applications: WO2010IB02518

METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS

A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.
Related applications: EP20100838298, WO2010US61058, EP20100838298, EP20180203249, CA20102784568

NUCLEIC ACID-CONTAINING LIPID PARTICLES AND RELATED METHODS

The present invention provides a method for preparing nucleic acid-lipid nanoparticles comprising the cationic lipid DLinKC2-DMA using a microfluidic mixing device, wherein the resulting nucleic acid-lipid nanoparticles exhibit smaller particle diameter and greater core density than nucleic acid-lipid nanoparticles of the same formulation produced b\ the conventional preformed vesicle method
Related applications: CA20102816925, WO2010CA01766, EP20100851175, EP20100851175

LIMIT SIZE LIPID NANOPARTICLES AND RELATED METHODS

Limit size lipid nanoparticles, methods for using the lipid nanoparticles, and methods and systems for making limit size lipid nanoparticles.
Related applications: EP20210169020, EP20120843980, WO2012CA00991, EP20160166730, CA20122853316

LIPID NANOPARTICLES FOR TRANSFECTION AND RELATED METHODS

Transfection reagent composition, lipid nanoparticles prepared from the transfection reagent composition, kits that include the transfection reagent composition, and methods for making and using lipid nanoparticles prepared from the transfection reagent composition. Lipids when dispersed in aqueous media readily form liposomes, such as unilamellar vesicles and multilamellar vesicles. Liposomes have been used successfully to encapsulate and deliver a wide range of chemicals including nucleic...
Related applications: WO2014US29116, EP20140785963, EP20140785963, CA20142906732

LIPID-LINKED PRODRUGS

This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.
Related applications: WO2016CA00322, EP20160877035

COMPOSITIONS AND SYSTEMS COMPRISING TRANSFECTION-COMPETENT VESICLES FREE OF ORGANIC-SOLVENTS AND DETERGENTS AND METHODS RELATED THERETO

Lipid-based vesicles, typically herein called transfection competent vesicles (TCVs), configured to safely and efficiently deliver DNA, RNA, other nucleic acid and protein cargoes into target cells. The safety and efficiency are each, and both, achieved in part by eliminating organic solvents such as ethanol and detergents such as sodium dodecyl sulfate from the TCV loading processes (i.e., inserting a cargo into the TCV), TCV storage processes, and/or TCV delivery processes. The cargoes can...
Related applications: WO2019US55472, EP20190871608

METHODS AND COMPOSITIONS FOR MODULATING PLASMINOGEN

The present disclosure provides a duplex or single-stranded siRNA molecule against plasminogen, the siRNA molecule containing modified or unmodified nucleotides and wherein at least one strand of the duplex or the single-stranded siRNA has a sequence that has at least 80% sequence identity to any one of SEQ ID NOs: 1 to 28. Further provided is a duplex or single-stranded siRNA molecule against plasminogen, the siRNA molecule containing modified or unmodified nucleotides and is between 25 and...
Related applications: WO2022CA50213

RED-SHIFTED PHOTOLIPIDS AND NANOPARTICLES FORMED FROM SAME

Provided are photoswitchable glycerophospholipids having a photoswitchable group having the following structure: or The photoswitchable glycerophospholipids can be isomerized by red spectral light. Also disclosed are nanovesicles (e.g., liposomes). Also disclosed are methods of making the photoswitchable glycerophospholipids and nanovesicles formed therefrom. The present disclosure further provides methods of using the nanovesicles, e.g., for targeted delivery of cargo. A photoswitchable...
Related applications: WO2022US21150